Rob Pieters

1.5k total citations
27 papers, 957 citations indexed

About

Rob Pieters is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Rob Pieters has authored 27 papers receiving a total of 957 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Public Health, Environmental and Occupational Health, 12 papers in Hematology and 10 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Rob Pieters's work include Acute Lymphoblastic Leukemia research (18 papers), Acute Myeloid Leukemia Research (9 papers) and Childhood Cancer Survivors' Quality of Life (9 papers). Rob Pieters is often cited by papers focused on Acute Lymphoblastic Leukemia research (18 papers), Acute Myeloid Leukemia Research (9 papers) and Childhood Cancer Survivors' Quality of Life (9 papers). Rob Pieters collaborates with scholars based in Netherlands, Germany and United States. Rob Pieters's co-authors include A. Veerman, Herbert M. Pinedo, C.H.N. Veenhof, Manon Huizing, Jan B. Vermorken, Jos H. Beijnen, W.W. ten Bokkel Huinink, E. Klumper, Marry M. van den Heuvel‐Eibrink and Gerrit Jansen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer.

In The Last Decade

Rob Pieters

25 papers receiving 925 citations

Peers

Countries citing papers authored by Rob Pieters

Since Specialization

Citations

This map shows the geographic impact of Rob Pieters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rob Pieters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rob Pieters more than expected).

Fields of papers citing papers by Rob Pieters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rob Pieters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rob Pieters. The network helps show where Rob Pieters may publish in the future.

Co-authorship network of co-authors of Rob Pieters

This figure shows the co-authorship network connecting the top 25 collaborators of Rob Pieters. A scholar is included among the top collaborators of Rob Pieters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rob Pieters. Rob Pieters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	IGH rearrangements in Down syndrome acute lymphoblastic leukemia 2025 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Aurélie Boeree, Edwin Sonneveld, Anthony V. Moorman, (unknown), Rosemary Sutton, H. Berna Beverloo, Rob Pieters, C. Michel Zwaan, Monique L. den Boer, Judith M. Boer	1
2	KMT2A-rearranged acute lymphoblastic leukemia in infants: current progress and challenges 2025 ·Haematologica ·Janine Stutterheim, Inge M. van der Sluis, (unknown), Rob Pieters, Ronald W. Stam	1
3	CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in KMT2A-Rearranged Acute Lymphoblastic Leukemia 2023 ·International Journal of Molecular Sciences ·Pauline Schneider, (unknown), Susan T.C.J.M. Arentsen-Peters, (unknown), Dedeke Rockx-Brouwer, (unknown), (unknown), (unknown), Jarno Drost, Rob Pieters, Ronald W. Stam	1
4	Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders 2022 ·Blood ·Rob Pieters, Hester A. de Groot‐Kruseman, (unknown), (unknown), Edwin Sonneveld, Marta Fiocco, Vincent H. J. van der Velden, Berna Beverloo, Marc Bierings, Válerie de Haas, Peter M. Hoogerbrugge, Inge M. van der Sluis, Wim J. E. Tissing, Margreet A. Veening, Judith M. Boer, Monique L. den Boer	2
5	Effect of post-consolidation regimen on symptomatic osteonecrosis in three DCOG acute lymphoblastic leukemia protocols 2020 ·Haematologica ·(unknown), Hester A. de Groot‐Kruseman, Marta Fiocco, Maarten H. Lequin, Sebastian Neggers, Saskia M.F. Pluijm, Inge M. van der Sluis, Rob Pieters, Marry M. van den Heuvel‐Eibrink	7
6	The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia 2014 ·Haematologica ·(unknown), Saskia M.F. Pluijm, Hester A. de Groot‐Kruseman, M.L. te Winkel, (unknown), Erica L T van den Akker, (unknown), Henk van den Berg, J. A. Leeuw, Marrie C.A. Bruin, Dorine Bresters, A. Veerman, Rob Pieters, Marry M. van den Heuvel‐Eibrink	38
7	Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL 2013 ·Leukemia ·J A P Spijkers-Hagelstein, Sandra S. Pinhanços, Pauline Schneider, Rob Pieters, Ronald W. Stam	24
8	Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells 2013 ·Haematologica ·(unknown), (unknown), Michael J. Allen, Daniel Williamson, Steven C. Clifford, Martin A. Horstmann, H.N. Caron, Rob Pieters, Monique L. den Boer	20
9	The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance 2013 ·Haematologica ·Ingrid M. Ariës, Birgitte Rønde Hansen, Troels Koch, (unknown), William E. Evans, Rob Pieters, Monique L. den Boer	19
10	Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia 2013 ·Haematologica ·I. van der Sluis, Anja Möricke, (unknown), Arend von Stackelberg, Wolfgang Holter, Thomas Klingebiel, Christian Flotho, (unknown), Wim J. E. Tissing, Marc Bierings, (unknown), Uwe Pichlmeier, (unknown), Rob Pieters	14
11	The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97) 2011 ·Haematologica ·Gabriele Escherich, (unknown), U. Göbel, Ulrike Graubner, Arnulf Pekrun, Norbert Jorch, Gertjan J.L. Kaspers, Martin Zimmermann, Udo zur Stadt, K.M. Kazemier, Rob Pieters, Monique L. den Boer, (unknown), Gritta Janka, (unknown)	18
12	Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia 2010 ·Haematologica ·Diana Schotte, Ellen Lange-Turenhout, Dominique J. P. M. Stumpel, Ronald W. Stam, Jessica G. C. A. M. Buijs-Gladdines, Jules P.P. Meijerink, Rob Pieters, Monique L. den Boer	78
13	Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia 2009 ·Haematologica ·M.L. te Winkel, Robert D. van Beek, Sabine M.P.F. de Muinck Keizer‐Schrama, André G. Uitterlinden, Wim C.J. Hop, Rob Pieters, Marry M. van den Heuvel‐Eibrink	32
14	Protection against chemotherapy induced mucositis by TGF‐β₂ in childhood cancer patients: Results from a randomized cross‐over study 2006 ·Pediatric Blood & Cancer ·Barbara A. E. de Koning, (unknown), (unknown), Karel Hählen, Hans A. Büller, Rob Pieters	22
15	The role of impaired transport in (pre)clinical resistance to methotrexate: insights on new antifolates 1998 ·Drug Resistance Updates ·Gerrit Jansen, Rob Pieters	24
16	MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia 1997 ·British Journal of Haematology ·Marry M. van den Heuvel‐Eibrink, Bronno van der Holt, Peter A.W. te Boekhorst, Rob Pieters, Martijn Schoester, Bob Löwenberg, Pieter Sonneveld	84
17	IN VITRO RESISTANCE TO CYTOSINE ARABINOSIDE, NOT TO DAUNORUBICIN, IS ASSOCIATED WITH THE RISK OF RELAPSE IN DE NOVO ACUTE MYELOID LEUKAEMIA 1996 ·British Journal of Haematology ·E. Klumper, Gert J. Ossenkoppele, Rob Pieters, (unknown), (unknown), (unknown), Guus Westra, A. Veerman	42
18	Taxanes: A New Class of Antitumor Agents 1995 ·Cancer Investigation ·Manon Huizing, (unknown), Rob Pieters, W.W. ten Bokkel Huinink, C.H.N. Veenhof, Jan B. Vermorken, Herbert M. Pinedo, Jos H. Beijnen	238
19	A Double-Blind Randomized Crossover Study to Compare the Antiemetic Efficacy of 250 mg with 500 mg Methylprednisolone Succinate (Solu-Medrol) as a Single Intravenous Dose in Patients Treated with Noncisplatin Chemotherapy 1993 ·Oncology ·Rob Pieters, Jan B. Vermorken, H.E. Gall, J. J. P. Nauta, A. C. Van Loenen, C.J. van Groeningen, (unknown), (unknown), H. M. Pinedo	3
20	Bone marrow magnetic resonance studies in childhood leukemia. Evaluation of osteonecrosis 1987 ·Cancer ·Rob Pieters, (unknown), A. Veerman, Annette H. M. Taets van Amerongen, (unknown), Richard P. Golding	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact